Brokerages have cut the company's FY16 earnings estimates between 16% and 29% with target prices too coming down to the Rs 700-800 band

FIIs are looking at the long-term story and initiatives of Indian pharma companies to transform themselves into global entities.

Telcos have indicated that rates will have to be raised, as higher volumes alone will not suffice to meet the higher costs.

The challenge of merging Ranbaxy into the company has not been factored in.

Given the better growth in JLR sales and improving domestic sales, nearly 90 per cent of the analysts covering the stock have a 'Buy' rating.

Maruti has improved its sales in the recent past.

Maruti is expected to post double-digit growth on product launches and good demand for entry-level cars.

To focus on molecules at advanced stage of development; move to impact 200 scientists.

The Network18 stock is down 4.2 per cent after the declaration of results to Rs 49.50 currently.

US will remain a growth driver, with launches & existing portfolios set to result in 15% growth for FY15.

Favourable response to launches, recovery in CVs will aid growth.

Bharti'suarterly revenue run rate continues to be hover around the $1.2 billion mar